Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews Q2 Revenues Drop 78 Percent

NEW YORK (GenomeWeb) – GeneNews reported today a 78 percent decrease in second quarter revenues, reflecting a drop off in sales of its ColonSentry colorectal cancer blood test and other diagnostics.

For the three-month period ended June 30, GeneNews' revenues — generated entirely through the sale of its diagnostics — fell to $113,513 from $527,347 a year earlier. The company did, however, process more than 1,800 tests through its recently acquired clinical reference lab Innovative Diagnostic Laboratory (IDL), three times more than the number processed in the first quarter of the year.

The Canadian firm's net loss in the quarter was down 70 percent to $456,828, or $.01 per share, from $1.5 million, or $.02 per share, in the same period the year before. GeneNews in part attributed the decrease to a $1.3 million change in revaluation of warrants associated with repricing of warrants in June.

Also contributing to the narrowed loss was a slight decrease in second quarter general and administrative costs to $1.1 million from $1.2 million the year before. GeneNews reported no research and development spending in the quarter.

At the end of June, GeneNews had cash and cash equivalents totaling $61,154.

During the second quarter, GeneNews announced that it had signed a binding agreement with Milost Global for up to $10 million in equity and debt financing, with a $3 million initial drawdown. And last month, the firm announced a warrant exercise incentive program that will close August 31.

"We estimate our outstanding 2017 billings at approximately $1.4 million and continue to anticipate that our recognized revenue will begin to grow in the months ahead," GeneNews Chairman and CEO James Howard-Tripp said in a statement.

Additionally, the company said it has undertaken a number of initiatives to boost revenues including adding blood-draw facilities, including a mobile phlebotomist component, to support outreach to large healthcare systems, hospitals, clinically integrated networks, large physician groups, and specific at-risk communities. GeneNews said it now has access to over 8,000 blood-draw sites in the US.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.